Published in Nat Rev Microbiol on February 02, 2010
Novel surveillance network for norovirus gastroenteritis outbreaks, United States. Emerg Infect Dis (2011) 3.06
Serological correlate of protection against norovirus-induced gastroenteritis. J Infect Dis (2010) 2.21
Recombination within the pandemic norovirus GII.4 lineage. J Virol (2013) 1.93
Norovirus GII.4 strain antigenic variation. J Virol (2010) 1.73
Norovirus-host interaction: multi-selections by human histo-blood group antigens. Trends Microbiol (2011) 1.73
Genetic mapping of a highly variable norovirus GII.4 blockade epitope: potential role in escape from human herd immunity. J Virol (2011) 1.53
Structural analysis of histo-blood group antigen binding specificity in a norovirus GII.4 epidemic variant: implications for epochal evolution. J Virol (2011) 1.53
Comprehensive review of human sapoviruses. Clin Microbiol Rev (2015) 1.48
Advances in norovirus biology. Cell Host Microbe (2014) 1.45
Norovirus. Clin Microbiol Rev (2015) 1.41
Norovirus immunity and the great escape. PLoS Pathog (2012) 1.40
Rapid emergence and predominance of a broadly recognizing and fast-evolving norovirus GII.17 variant in late 2014. Nat Commun (2015) 1.40
Histo-blood group antigen-like substances of human enteric bacteria as specific adsorbents for human noroviruses. J Virol (2013) 1.39
Protruding domain of capsid protein is necessary and sufficient to determine murine norovirus replication and pathogenesis in vivo. J Virol (2012) 1.34
Histo-blood group antigens act as attachment factors of rabbit hemorrhagic disease virus infection in a virus strain-dependent manner. PLoS Pathog (2011) 1.31
Monoclonal antibody-based antigenic mapping of norovirus GII.4-2002. J Virol (2011) 1.29
Comparative evolution of GII.3 and GII.4 norovirus over a 31-year period. J Virol (2011) 1.28
Identification of immune and viral correlates of norovirus protective immunity through comparative study of intra-cluster norovirus strains. PLoS Pathog (2013) 1.22
Genetic diversity and distribution of human norovirus in China (1999-2011). Biomed Res Int (2014) 1.17
High-resolution x-ray structure and functional analysis of the murine norovirus 1 capsid protein protruding domain. J Virol (2010) 1.13
Emergence of a new norovirus GII.4 variant and changes in the historical biennial pattern of norovirus outbreak activity in Alberta, Canada, from 2008 to 2013. J Clin Microbiol (2013) 1.10
Broad blockade antibody responses in human volunteers after immunization with a multivalent norovirus VLP candidate vaccine: immunological analyses from a phase I clinical trial. PLoS Med (2015) 1.09
Murine noroviruses bind glycolipid and glycoprotein attachment receptors in a strain-dependent manner. J Virol (2012) 1.05
Norovirus RNA synthesis is modulated by an interaction between the viral RNA-dependent RNA polymerase and the major capsid protein, VP1. J Virol (2012) 1.04
Host genetic factors affect susceptibility to norovirus infections in Burkina Faso. PLoS One (2013) 1.04
Viva la revolución: rethinking influenza a virus antigenic drift. Curr Opin Virol (2011) 1.02
Transmission of viruses through shellfish: when specific ligands come into play. Curr Opin Virol (2011) 1.02
Human norovirus transmission and evolution in a changing world. Nat Rev Microbiol (2016) 1.01
Norovirus in healthcare settings. Curr Opin Infect Dis (2014) 0.98
Characterization of blockade antibody responses in GII.2.1976 Snow Mountain virus-infected subjects. J Virol (2013) 0.98
Glycosphingolipids as receptors for non-enveloped viruses. Viruses (2010) 0.98
Identification of human single-chain antibodies with broad reactivity for noroviruses. Protein Eng Des Sel (2014) 0.95
Molecular evolution of GII-4 Norovirus strains. PLoS One (2012) 0.95
Phylodynamic inference and model assessment with approximate bayesian computation: influenza as a case study. PLoS Comput Biol (2012) 0.94
Inactivation of a foodborne norovirus outbreak strain with nonthermal atmospheric pressure plasma. MBio (2015) 0.92
Identification of a Broadly Cross-Reactive Epitope in the Inner Shell of the Norovirus Capsid. PLoS One (2013) 0.92
Inactivation of norovirus on dry copper alloy surfaces. PLoS One (2013) 0.91
Bovine norovirus: carbohydrate ligand, environmental contamination, and potential cross-species transmission via oysters. Appl Environ Microbiol (2010) 0.90
Covariation of major and minor viral capsid proteins in norovirus genogroup II genotype 4 strains. J Virol (2011) 0.90
Non-encapsidation activities of the capsid proteins of positive-strand RNA viruses. Virology (2013) 0.89
Binding to histo-blood group antigen-expressing bacteria protects human norovirus from acute heat stress. Front Microbiol (2015) 0.87
Progress towards the prevention and treatment of norovirus infections. Future Microbiol (2013) 0.87
Structural analysis of determinants of histo-blood group antigen binding specificity in genogroup I noroviruses. J Virol (2014) 0.86
A novel norovirus GII.17 lineage contributed to adult gastroenteritis in Shanghai, China, during the winter of 2014–2015. Emerg Microbes Infect (2015) 0.85
Genetic Analysis of Norovirus GII.4 Variant Strains Detected in Outbreaks of Gastroenteritis in Yokohama, Japan, from the 2006-2007 to the 2013-2014 Seasons. PLoS One (2015) 0.83
Norovirus diversity in diarrheic children from an African-descendant settlement in Belém, Northern Brazil. PLoS One (2013) 0.83
Prevalence and genetic diversity of noroviruses in adults with acute gastroenteritis in Huzhou, China, 2013-2014. Arch Virol (2015) 0.83
Flexibility in surface-exposed loops in a virus capsid mediates escape from antibody neutralization. J Virol (2014) 0.83
Environmental transmission of human noroviruses in shellfish waters. Appl Environ Microbiol (2014) 0.82
The dynamics of GII.4 Norovirus in Ho Chi Minh City, Vietnam. Infect Genet Evol (2013) 0.80
Norovirus GII.4 virus-like particles recognize galactosylceramides in domains of planar supported lipid bilayers. Angew Chem Int Ed Engl (2012) 0.80
A Multi-Site Study of Norovirus Molecular Epidemiology in Australia and New Zealand, 2013-2014. PLoS One (2016) 0.79
Pathogen-inspired drug delivery to the central nervous system. Tissue Barriers (2014) 0.78
Recent Advances in the Discovery of Norovirus Therapeutics. J Med Chem (2015) 0.78
Norovirus RNA-dependent RNA polymerase is phosphorylated by an important survival kinase, Akt. J Virol (2011) 0.78
Effects of Abiotic and Biotic Stresses on the Internalization and Dissemination of Human Norovirus Surrogates in Growing Romaine Lettuce. Appl Environ Microbiol (2015) 0.78
Complete genome of the human norovirus GIV.1 strain Lake Macquarie virus. J Virol (2012) 0.77
Molecular characterization of noroviruses and HBGA from infected Quilombola children in Espirito Santo State, Brazil. PLoS One (2013) 0.77
Molecular epidemiology of norovirus in South Korea. BMB Rep (2015) 0.77
Antiviral targets of human noroviruses. Curr Opin Virol (2016) 0.77
Current tools for norovirus drug discovery. Expert Opin Drug Discov (2016) 0.76
Newly isolated mAbs broaden the neutralizing epitope in murine norovirus. J Gen Virol (2014) 0.76
Childhood gastroenteritis--the rise of norovirus. Nat Rev Gastroenterol Hepatol (2013) 0.75
Complete nucleotide sequence analysis of the norovirus GII.4 Sydney variant in South Korea. Biomed Res Int (2015) 0.75
Clinical and epidemiological characteristics of norovirus gastroenteritis among hospitalized children in Lebanon. World J Gastroenterol (2016) 0.75
Personalized genetic testing and norovirus susceptibility. Can J Infect Dis Med Microbiol (2014) 0.75
Genome Sequence of Enterobacter cloacae Strain SENG-6, a Bacterium Producing Histo-Blood Group Antigen-Like Substances That Can Bind with Human Noroviruses. Genome Announc (2016) 0.75
Development of enhanced primer sets for detection of norovirus. Biomed Res Int (2015) 0.75
Norovirus vaccines: Correlates of protection, challenges and limitations. Hum Vaccin Immunother (2016) 0.75
Genetic and Epidemiologic Trends of Norovirus Outbreaks in the United States from 2013 to 2016 Demonstrated Emergence of Novel GII.4 Recombinant Viruses. J Clin Microbiol (2017) 0.75
Human norovirus detection and production, quantification, and storage of virus-like particles. Curr Protoc Microbiol (2013) 0.75
Evolutionary and functional implications of hypervariable loci within the skin virome. PeerJ (2017) 0.75
Norovirus drug candidates that inhibit viral capsid attachment to human histo-blood group antigens. Antiviral Res (2016) 0.75
Pattern of activation of human antigen presenting cells by genotype GII.4 norovirus virus-like particles. J Transl Med (2013) 0.75
Structural basis for norovirus neutralization by an HBGA blocking human IgA antibody. Proc Natl Acad Sci U S A (2016) 0.75
Evolutionary Constraints on the Norovirus Pandemic Variant GII.4_2006b over the Five-Year Persistence in Japan. Front Microbiol (2017) 0.75
MRBAYES: Bayesian inference of phylogenetic trees. Bioinformatics (2001) 101.31
Food-related illness and death in the United States. Emerg Infect Dis (1999) 39.22
Comparative protein structure modeling of genes and genomes. Annu Rev Biophys Biomol Struct (2000) 17.81
Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature (2008) 10.80
Visualization by immune electron microscopy of a 27-nm particle associated with acute infectious nonbacterial gastroenteritis. J Virol (1972) 9.12
Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein. J Virol (1992) 8.35
Norovirus classification and proposed strain nomenclature. Virology (2005) 7.69
Human susceptibility and resistance to Norwalk virus infection. Nat Med (2003) 7.07
X-ray crystallographic structure of the Norwalk virus capsid. Science (1999) 6.58
STAT1-dependent innate immunity to a Norwalk-like virus. Science (2003) 6.35
Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med (2003) 6.25
Norwalk virus genome cloning and characterization. Science (1990) 5.83
Norwalk virus infection and disease is associated with ABO histo-blood group type. J Infect Dis (2002) 5.09
Epidemiologic and molecular trends of "Norwalk-like viruses" associated with outbreaks of gastroenteritis in the United States. J Infect Dis (2002) 4.88
Clinical immunity in acute gastroenteritis caused by Norwalk agent. N Engl J Med (1977) 4.80
Norwalk virus binds to histo-blood group antigens present on gastroduodenal epithelial cells of secretor individuals. Gastroenterology (2002) 4.13
Phylogenetic analysis of the complete genome of 18 Norwalk-like viruses. Virology (2002) 3.79
Norovirus and histo-blood group antigens: demonstration of a wide spectrum of strain specificities and classification of two major binding groups among multiple binding patterns. J Virol (2005) 3.74
Epochal evolution of GGII.4 norovirus capsid proteins from 1995 to 2006. J Virol (2007) 3.71
Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology (1997) 3.62
Structural basis for the recognition of blood group trisaccharides by norovirus. J Virol (2007) 3.58
Comparison of three agents of acute infectious nonbacterial gastroenteritis by cross-challenge in volunteers. J Infect Dis (1974) 3.10
The origin of genetic information: viruses as models. Gene (1993) 2.90
Mutations within the P2 domain of norovirus capsid affect binding to human histo-blood group antigens: evidence for a binding pocket. J Virol (2003) 2.82
Correlation of patient immune responses with genetically characterized small round-structured viruses involved in outbreaks of nonbacterial acute gastroenteritis in the United States, 1990 to 1995. J Med Virol (1997) 2.70
Multiple-challenge study of host susceptibility to Norwalk gastroenteritis in US adults. J Infect Dis (1990) 2.63
Cellular and humoral immunity following Snow Mountain virus challenge. J Virol (2005) 2.59
Comparison of the reactivities of baculovirus-expressed recombinant Norwalk virus capsid antigen with those of the native Norwalk virus antigen in serologic assays and some epidemiologic observations. J Clin Microbiol (1993) 2.58
Atomic resolution structural characterization of recognition of histo-blood group antigens by Norwalk virus. Proc Natl Acad Sci U S A (2008) 2.54
The epidemiologic and clinical importance of norovirus infection. Gastroenterol Clin North Am (2006) 2.49
Simultaneous detection and genotyping of "Norwalk-like viruses" by oligonucleotide array in a reverse line blot hybridization format. J Clin Microbiol (2000) 2.49
Three-dimensional structure of baculovirus-expressed Norwalk virus capsids. J Virol (1994) 2.46
Structural requirements for the assembly of Norwalk virus-like particles. J Virol (2002) 2.38
Evolution of human calicivirus RNA in vivo: accumulation of mutations in the protruding P2 domain of the capsid leads to structural changes and possibly a new phenotype. J Virol (2003) 2.37
Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles. J Virol (2000) 2.09
Norovirus activity--United States, 2002. MMWR Morb Mortal Wkly Rep (2003) 1.99
Norwalk-like viruses: demonstration of genomic diversity by polymerase chain reaction. J Clin Microbiol (1993) 1.96
Norovirus pathogenesis: mechanisms of persistence and immune evasion in human populations. Immunol Rev (2008) 1.96
A homozygous nonsense mutation (428G-->A) in the human secretor (FUT2) gene provides resistance to symptomatic norovirus (GGII) infections. J Virol (2005) 1.93
The G428A nonsense mutation in FUT2 provides strong but not absolute protection against symptomatic GII.4 Norovirus infection. PLoS One (2009) 1.89
Structural basis for the receptor binding specificity of Norwalk virus. J Virol (2008) 1.82
RNA virus evolution and the control of viral disease. Prog Drug Res (1989) 1.74
Multivalent norovirus vaccines induce strong mucosal and systemic blocking antibodies against multiple strains. Vaccine (2006) 1.74
Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector. J Virol (1997) 1.73
Heterotypic humoral and cellular immune responses following Norwalk virus infection. J Virol (2009) 1.70
Pathogenesis and immune responses in gnotobiotic calves after infection with the genogroup II.4-HS66 strain of human norovirus. J Virol (2007) 1.70
Immune mechanisms responsible for vaccination against and clearance of mucosal and lymphatic norovirus infection. PLoS Pathog (2008) 1.69
Antibody is critical for the clearance of murine norovirus infection. J Virol (2008) 1.69
A viral vaccine vector that expresses foreign genes in lymph nodes and protects against mucosal challenge. J Virol (1996) 1.68
Association of histo-blood group antigens and susceptibility to norovirus infections. J Infect Dis (2005) 1.68
Noroviruses distinguish between type 1 and type 2 histo-blood group antigens for binding. J Virol (2008) 1.65
Molecular characterization of bovine enteric caliciviruses: a distinct third genogroup of noroviruses (Norwalk-like viruses) unlikely to be of risk to humans. J Virol (2003) 1.64
Analysis of amino acid variation in the P2 domain of the GII-4 norovirus VP1 protein reveals putative variant-specific epitopes. PLoS One (2008) 1.61
Expression and self-assembly of norwalk virus capsid protein from venezuelan equine encephalitis virus replicons. J Virol (2002) 1.60
Vaccination and antigenic drift in influenza. Vaccine (2008) 1.56
Structural studies of recombinant Norwalk capsids. J Infect Dis (2000) 1.52
Herd immunity to GII.4 noroviruses is supported by outbreak patient sera. J Virol (2009) 1.51
Deceptive imprinting and immune refocusing in vaccine design. Vaccine (2008) 1.47
Viral shedding and fecal IgA response after Norwalk virus infection. J Infect Dis (1995) 1.41
Alphavirus replicon particles as candidate HIV vaccines. IUBMB Life (2002) 1.41
Alphavirus vectors and vaccination. Rev Med Virol (2002) 1.40
Human noroviruses recognize sialyl Lewis x neoglycoprotein. Glycobiology (2008) 1.35
Detection of immunoglobulin M (IgM), IgA, and IgG Norwalk virus-specific antibodies by indirect enzyme-linked immunosorbent assay with baculovirus-expressed Norwalk virus capsid antigen in adult volunteers challenged with Norwalk virus. J Clin Microbiol (1994) 1.33
Epidemic dynamics and antigenic evolution in a single season of influenza A. Proc Biol Sci (2006) 1.32
Antibody prevalence and titer to norovirus (genogroup II) correlate with secretor (FUT2) but not with ABO phenotype or Lewis (FUT3) genotype. J Infect Dis (2006) 1.32
Cytokine and antibody responses in gnotobiotic pigs after infection with human norovirus genogroup II.4 (HS66 strain). J Virol (2007) 1.31
Enzyme immunoassay using baculovirus-expressed human calicivirus (Mexico) for the measurement of IgG responses and determining its seroprevalence in London, UK. J Med Virol (1995) 1.21
Influenza drift and epidemic size: the race between generating and escaping immunity. Theor Popul Biol (2004) 1.20
Capsid diversity in small round-structured viruses: molecular characterization of an antigenically distinct human enteric calicivirus. Virus Res (1995) 1.20
Cross-reactive memory CD8(+) T cells alter the immune response to heterologous secondary dengue virus infections in mice in a sequence-specific manner. J Infect Dis (2008) 1.19
Alphavirus-adjuvanted norovirus-like particle vaccines: heterologous, humoral, and mucosal immune responses protect against murine norovirus challenge. J Virol (2009) 1.17
Molecular epidemiology of norovirus in outbreaks of gastroenteritis in southwest Germany from 2001 to 2004. J Clin Microbiol (2006) 1.16
The genome of hawaii virus and its relationship with other members of the caliciviridae. Virus Genes (2001) 1.14
Seroprevalence against Norwalk-like human caliciviruses in beijing, China. J Med Virol (2000) 1.07
Outbreaks of gastroenteritis in elderly nursing homes and retirement facilities associated with human caliciviruses. J Med Virol (1996) 1.05
Norwalk virus infection and disease is associated with ABO histo-blood group type. J Infect Dis (2003) 1.04
Quasispecies dynamics and molecular evolution of human norovirus capsid P region during chronic infection. J Gen Virol (2009) 1.03
The discovery of the 27-nm Norwalk virus: an historic perspective. J Infect Dis (2000) 1.02
Genetic analysis of the capsid gene of genotype GII.2 noroviruses. J Virol (2008) 1.02
Prevalence of human calicivirus infections in Kenya as determined by enzyme immunoassays for three genogroups of the virus. J Clin Microbiol (1998) 1.01
Venezuelan equine encephalitis virus vectors expressing HIV-1 proteins: vector design strategies for improved vaccine efficacy. Vaccine (1999) 0.99
Combined single-clade candidate HIV-1 vaccines induce T cell responses limited by multiple forms of in vivo immune interference. Eur J Immunol (2007) 0.98
Prevalence of antibodies to the Hawaii strain of human calicivirus as measured by a recombinant protein based immunoassay. J Med Virol (1998) 0.93
Serological responses among teenagers after natural exposure to Norwalk virus. J Infect Dis (1984) 0.92
Avoiding deceptive imprinting of the immune response to HIV-1 infection in vaccine development. Int Rev Immunol (2004) 0.89
Antibody prevalence and immunoglobulin IgG subclass pattern to Norwalk virus in Sweden. J Med Virol (1995) 0.89
Epidemiological study of prevalence of genogroup II human calicivirus (Mexico virus) infections in Japan and Southeast Asia as determined by enzyme-linked immunosorbent assays. J Clin Microbiol (1998) 0.86
Analysis of Venezuelan equine encephalitis replicon particles packaged in different coats. PLoS One (2008) 0.84
[Genomic organization of Norwalk-like viruses and functions of viral gene products]. Nihon Rinsho (2002) 0.78
Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. J Virol (2013) 4.98
Mechanisms of GII.4 norovirus persistence in human populations. PLoS Med (2008) 4.57
Systematic assembly of a full-length infectious cDNA of mouse hepatitis virus strain A59. J Virol (2002) 4.29
Norwalk virus: how infectious is it? J Med Virol (2008) 3.93
Genetic analysis of complex traits in the emerging Collaborative Cross. Genome Res (2011) 3.25
Binding of Norwalk virus-like particles to ABH histo-blood group antigens is blocked by antisera from infected human volunteers or experimentally vaccinated mice. J Virol (2002) 2.98
Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci U S A (2003) 2.82
Recombination, reservoirs, and the modular spike: mechanisms of coronavirus cross-species transmission. J Virol (2009) 2.60
Cellular and humoral immunity following Snow Mountain virus challenge. J Virol (2005) 2.59
Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci U S A (2012) 2.42
Severe acute respiratory syndrome coronavirus group-specific open reading frames encode nonessential functions for replication in cell cultures and mice. J Virol (2005) 2.22
Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import factors on the rough endoplasmic reticulum/Golgi membrane. J Virol (2007) 2.18
Rapid generation of a mouse model for Middle East respiratory syndrome. Proc Natl Acad Sci U S A (2014) 2.17
Severe acute respiratory syndrome coronavirus infection of human ciliated airway epithelia: role of ciliated cells in viral spread in the conducting airways of the lungs. J Virol (2005) 2.05
Immunogenetic mechanisms driving norovirus GII.4 antigenic variation. PLoS Pathog (2012) 2.02
Synthetic recombinant bat SARS-like coronavirus is infectious in cultured cells and in mice. Proc Natl Acad Sci U S A (2008) 1.97
Norovirus pathogenesis: mechanisms of persistence and immune evasion in human populations. Immunol Rev (2008) 1.96
A decade after SARS: strategies for controlling emerging coronaviruses. Nat Rev Microbiol (2013) 1.94
Heterologous gene expression from transmissible gastroenteritis virus replicon particles. J Virol (2002) 1.85
Norovirus capture with histo-blood group antigens reveals novel virus-ligand interactions. J Virol (2004) 1.80
Unique signatures of long noncoding RNA expression in response to virus infection and altered innate immune signaling. MBio (2010) 1.79
Severe acute respiratory syndrome coronavirus evades antiviral signaling: role of nsp1 and rational design of an attenuated strain. J Virol (2007) 1.75
Evidence supporting a zoonotic origin of human coronavirus strain NL63. J Virol (2012) 1.75
Multivalent norovirus vaccines induce strong mucosal and systemic blocking antibodies against multiple strains. Vaccine (2006) 1.74
Norovirus GII.4 strain antigenic variation. J Virol (2010) 1.73
Reverse genetics with a full-length infectious cDNA of the Middle East respiratory syndrome coronavirus. Proc Natl Acad Sci U S A (2013) 1.73
The nsp2 replicase proteins of murine hepatitis virus and severe acute respiratory syndrome coronavirus are dispensable for viral replication. J Virol (2005) 1.71
Heterotypic humoral and cellular immune responses following Norwalk virus infection. J Virol (2009) 1.70
Immune mechanisms responsible for vaccination against and clearance of mucosal and lymphatic norovirus infection. PLoS Pathog (2008) 1.69
Antibody is critical for the clearance of murine norovirus infection. J Virol (2008) 1.69
Tropism of and innate immune responses to the novel human betacoronavirus lineage C virus in human ex vivo respiratory organ cultures. J Virol (2013) 1.68
Infidelity of SARS-CoV Nsp14-exonuclease mutant virus replication is revealed by complete genome sequencing. PLoS Pathog (2010) 1.67
Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-kappaB signaling. J Virol (2009) 1.58
Natural strain variation and antibody neutralization of dengue serotype 3 viruses. PLoS Pathog (2010) 1.56
Single-amino-acid substitutions in open reading frame (ORF) 1b-nsp14 and ORF 2a proteins of the coronavirus mouse hepatitis virus are attenuating in mice. J Virol (2005) 1.54
Genetic mapping of a highly variable norovirus GII.4 blockade epitope: potential role in escape from human herd immunity. J Virol (2011) 1.53
Herd immunity to GII.4 noroviruses is supported by outbreak patient sera. J Virol (2009) 1.51
Emergence of new pandemic GII.4 Sydney norovirus strain correlates with escape from herd immunity. J Infect Dis (2013) 1.47
MyD88 is required for protection from lethal infection with a mouse-adapted SARS-CoV. PLoS Pathog (2008) 1.47
Modeling host genetic regulation of influenza pathogenesis in the collaborative cross. PLoS Pathog (2013) 1.43
Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus. MBio (2013) 1.41
Cynomolgus macaque as an animal model for severe acute respiratory syndrome. PLoS Med (2006) 1.40
Norovirus immunity and the great escape. PLoS Pathog (2012) 1.40
Systemic, mucosal, and heterotypic immune induction in mice inoculated with Venezuelan equine encephalitis replicons expressing Norwalk virus-like particles. J Virol (2002) 1.36
Emergence of a norovirus GII.4 strain correlates with changes in evolving blockade epitopes. J Virol (2012) 1.36
Expression quantitative trait Loci for extreme host response to influenza a in pre-collaborative cross mice. G3 (Bethesda) (2012) 1.35
SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon. Curr Opin Virol (2012) 1.33
Cleavage between replicase proteins p28 and p65 of mouse hepatitis virus is not required for virus replication. J Virol (2004) 1.32
SARS-CoV pathogenesis is regulated by a STAT1 dependent but a type I, II and III interferon receptor independent mechanism. PLoS Pathog (2010) 1.32
Monoclonal antibody-based antigenic mapping of norovirus GII.4-2002. J Virol (2011) 1.29
A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease. Nat Med (2012) 1.26
Norovirus infectivity in humans and persistence in water. Appl Environ Microbiol (2011) 1.26
Systematic assembly of a full-length infectious clone of human coronavirus NL63. J Virol (2008) 1.23
Evaluation of serologic and antigenic relationships between middle eastern respiratory syndrome coronavirus and other coronaviruses to develop vaccine platforms for the rapid response to emerging coronaviruses. J Infect Dis (2013) 1.23
Characterization of the homo- and heterotypic immune responses after natural norovirus infection. J Med Virol (2005) 1.23
Processing of open reading frame 1a replicase proteins nsp7 to nsp10 in murine hepatitis virus strain A59 replication. J Virol (2007) 1.22
Rewiring the severe acute respiratory syndrome coronavirus (SARS-CoV) transcription circuit: engineering a recombination-resistant genome. Proc Natl Acad Sci U S A (2006) 1.22
Retracted Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity. Proc Natl Acad Sci U S A (2014) 1.19
Coronaviruses: an RNA proofreading machine regulates replication fidelity and diversity. RNA Biol (2011) 1.18
Characterization of emerging GII.g/GII.12 noroviruses from a gastroenteritis outbreak in the United States in 2010. J Clin Microbiol (2011) 1.18
Alphavirus-adjuvanted norovirus-like particle vaccines: heterologous, humoral, and mucosal immune responses protect against murine norovirus challenge. J Virol (2009) 1.17
Improved quality control processing of peptide-centric LC-MS proteomics data. Bioinformatics (2011) 1.15
Crystal structure of the receptor-binding domain from newly emerged Middle East respiratory syndrome coronavirus. J Virol (2013) 1.15
Development and characterization of a reverse genetic system for studying dengue virus serotype 3 strain variation and neutralization. PLoS Negl Trop Dis (2012) 1.14
Novel influenza virus NS1 antagonists block replication and restore innate immune function. J Virol (2008) 1.11
Mouse dipeptidyl peptidase 4 is not a functional receptor for Middle East respiratory syndrome coronavirus infection. J Virol (2014) 1.11
Amino acid substitutions in the S2 subunit of mouse hepatitis virus variant V51 encode determinants of host range expansion. J Virol (2007) 1.10
Attenuation and restoration of severe acute respiratory syndrome coronavirus mutant lacking 2'-o-methyltransferase activity. J Virol (2014) 1.10
Release of severe acute respiratory syndrome coronavirus nuclear import block enhances host transcription in human lung cells. J Virol (2013) 1.08
Molecular determinants of severe acute respiratory syndrome coronavirus pathogenesis and virulence in young and aged mouse models of human disease. J Virol (2011) 1.07
Effect of mutations in the mouse hepatitis virus 3'(+)42 protein binding element on RNA replication. J Virol (2005) 1.07
Escape from human monoclonal antibody neutralization affects in vitro and in vivo fitness of severe acute respiratory syndrome coronavirus. J Infect Dis (2010) 1.07
Successful vaccination strategies that protect aged mice from lethal challenge from influenza virus and heterologous severe acute respiratory syndrome coronavirus. J Virol (2010) 1.07
Murine hepatitis virus replicase protein nsp10 is a critical regulator of viral RNA synthesis. J Virol (2007) 1.06
Molecular pathology of emerging coronavirus infections. J Pathol (2015) 1.05
Analysis of murine hepatitis virus strain A59 temperature-sensitive mutant TS-LA6 suggests that nsp10 plays a critical role in polyprotein processing. J Virol (2007) 1.04
Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury. MBio (2013) 1.04
Molecular surveillance of enterovirus and norwalk-like virus in oysters relocated to a municipal-sewage-impacted gulf estuary. Appl Environ Microbiol (2003) 1.01
Zn(2+) inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. PLoS Pathog (2010) 0.99
Characterization of blockade antibody responses in GII.2.1976 Snow Mountain virus-infected subjects. J Virol (2013) 0.98
Transcriptomic analysis reveals a mechanism for a prefibrotic phenotype in STAT1 knockout mice during severe acute respiratory syndrome coronavirus infection. J Virol (2010) 0.95
A mouse model for Betacoronavirus subgroup 2c using a bat coronavirus strain HKU5 variant. MBio (2014) 0.95
mRNA display design of fibronectin-based intrabodies that detect and inhibit severe acute respiratory syndrome coronavirus nucleocapsid protein. J Biol Chem (2009) 0.92
Identification of cross-reactive norovirus CD4+ T cell epitopes. J Virol (2010) 0.91
SARS CoV replication and pathogenesis in human airway epithelial cultures. Adv Exp Med Biol (2006) 0.89
Severe acute respiratory syndrome coronavirus nsp9 dimerization is essential for efficient viral growth. J Virol (2009) 0.89
A network integration approach to predict conserved regulators related to pathogenicity of influenza and SARS-CoV respiratory viruses. PLoS One (2013) 0.87